Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)

被引:30
|
作者
Ozsvari, Bela [1 ,2 ]
Sotgia, Federica [1 ,2 ]
Simmons, Katie [3 ,4 ]
Trowbridge, Rachel [3 ,4 ]
Foster, Richard [3 ,4 ,5 ]
Lisanti, Michael P. [1 ,2 ]
机构
[1] Univ Salford, Sch Environm & Life Sci, Translat Med, Manchester, Lancs, England
[2] Univ Manchester, Paterson Inst, Withington, England
[3] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Leeds, W Yorkshire, England
[4] Univ Leeds, Fac Biol Sci, Astbury Ctr Struct Mol Biol, Leeds, W Yorkshire, England
[5] Univ Leeds, Fac Math & Phys Sci, Sch Chem, Leeds, W Yorkshire, England
关键词
ketone bodies; drug design; mitochondria; tumor-initiating cells; cancer stem-like cells; TUMOR-GROWTH; BODIES; METASTASIS; THERAPY;
D O I
10.18632/oncotarget.21259
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous studies have now well-established that epithelial cancer cells can utilize ketone bodies (3-hydroxybutyrate and aceto-acetate) as mitochondria) fuels, to actively promote tumor growth and metastatic dissemination. The two critical metabolic enzymes implicated in this process are OXCT1 and ACAT1, which are both mitochondrial proteins. Importantly, over-expression of OXCT1 or ACAT1 in human breast cancer cells is sufficient to genetically drive tumorigenesis and/or lung metastasis, validating that they indeed behave as metabolic "tumor promoters". Here, we decided to target these two enzymes, which give cancer cells the ability to recycle ketone bodies into Acetyl-CoA and, therefore, to produce increased ATP. Briefly, we used computational chemistry (in silico drug design) to select a sub-set of potentially promising compounds that spatially fit within the active site of these enzymes, based on their known 3D crystal structures. These libraries of compounds were then phenotypically screened for their effects on total cellular ATP levels. Positive hits were further validated by metabolic flux analysis. Our results indicated that four of these compounds effectively inhibited mitochondrial oxygen consumption. Two of these compounds also induced a reactive glycolytic phenotype in cancer cells. Most importantly, using the mammosphere assay, we showed that these compounds can be used to functionally inhibit cancer stem cell (CSC) activity and propagation. Finally, our molecular modeling studies directly show how these novel compounds are predicted to bind to the active catalytic sites of OXCT1 and ACAT1, within their Coenzyme A binding site. As such, we speculate that these mitochondrial inhibitors are partially mimicking the structure of Coenzyme A. Thus, we conclude that OXCT1 and ACAT1 are important new therapeutic targets for further drug development and optimization. We propose that this new class of drugs should be termed "mitoketoscins", to reflect that they were designed to target ketone re-utilization and mitochondrial function.
引用
收藏
页码:78340 / 78350
页数:11
相关论文
共 50 条
  • [1] Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism
    Fiorillo, Marco
    Peiris-Pages, Maria
    Sanchez-Alvarez, Rosa
    Bartella, Lucia
    Di Donna, Leonardo
    Dolce, Vincenza
    Sindona, Giovanni
    Sotgia, Federica
    Cappello, Anna Rita
    Lisanti, Michael P.
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 2018, 1859 (09): : 984 - 996
  • [2] Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast
    Ozsvari, Bela
    Fiorillo, Marco
    Bonuccelli, Gloria
    Cappello, Anna Rita
    Frattaruolo, Luca
    Sotgia, Federica
    Trowbridge, Rachel
    Foster, Richard
    Lisanti, Michael P.
    ONCOTARGET, 2017, 8 (40) : 67457 - 67472
  • [3] A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX
    Sotgia, Federica
    Ozsvari, Bela
    Fiorillo, Marco
    De Francesco, Ernestina Marianna
    Bonuccelli, Gloria
    Lisanti, Michael P.
    CELL CYCLE, 2018, 17 (17) : 2091 - 2100
  • [4] Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways
    Bonuccelli, Gloria
    Sotgia, Federica
    Lisanti, Michael P.
    AGING-US, 2018, 10 (08): : 1867 - 1883
  • [5] Inhibition of Breast Cancer Stem Cells (CSCs) by Novel STAT3 Inhibitors.
    Dave, B.
    Tweardy, D. J.
    Lewis, M. T.
    Chang, J. C.
    CANCER RESEARCH, 2009, 69 (24) : 587S - 588S
  • [6] Cancer stem cells (CSCs)
    Chulkova, Svetlana V.
    LEUKEMIA RESEARCH, 2019, 85 : S25 - S25
  • [7] Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)
    Ozsvari, Bela
    Sotgia, Federica
    Lisanti, Michael P.
    AGING-US, 2018, 10 (02): : 229 - 240
  • [8] Cancer stem cells (CSCs), cervical CSCs and targeted therapies
    Huang, Ruixia
    Rofstad, Einar K.
    ONCOTARGET, 2017, 8 (21) : 35351 - 35367
  • [9] Cancer stem cells (CSCs) in cancer progression and therapy
    Najafi, Masoud
    Farhood, Bagher
    Mortezaee, Keywan
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (06) : 8381 - 8395
  • [10] Targeting prostate cancer stem cells (CSCs) with the novel BET bromodomain (BRD) protein inhibitor OTX015
    Civenni, Gianluca
    Pedrani, Silvia
    Allegrini, Sara
    Bruccoleri, Antonina
    Albino, Domenico
    Pinton, Sandra
    Garcia-Escudero, Ramon
    Ouafik, L'Houcine
    Cvitkovic, Esteban
    Carbone, Giuseppina M.
    Catapano, Carlo V.
    CANCER RESEARCH, 2015, 75